Light Exposure to Prevent Frailty in Prostate Cancer Patients
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether systemic light exposure can prevent frailty in older men with prostate cancer undergoing hormone therapy. Hormone therapy often causes weakness, fatigue, and reduced activity. The study tests two light exposure methods using special glasses, with participants wearing them for 30 minutes each morning over several months. Men with prostate cancer who are beginning hormone treatment and have no major health issues may be suitable candidates for this study. As an Early Phase 1 trial, the research aims to understand how the treatment works in people, offering participants a chance to be among the first to explore this innovative approach.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications. However, it mentions that participants will be on hormonal therapy for prostate cancer, so you may need to continue those treatments.
What prior data suggests that systemic light exposure is safe for preventing frailty in prostate cancer patients?
Research has shown that bright light therapy is generally easy to use and has few side effects. For older men with prostate cancer, bright white light may help reduce tiredness and muscle weakness caused by hormone therapy. Although the safety of this light treatment is still under study, early results suggest it is a safe option for patients.12345
Why are researchers excited about this trial?
Researchers are excited about light exposure for preventing frailty in prostate cancer patients because it offers a non-invasive and easy-to-use option that differs from traditional treatments like medications or physical therapies. This approach uses Luminette glasses to deliver bright white light (BWL) or dim white light (DWL) daily, potentially boosting patients' energy and mood by regulating their circadian rhythms. Unlike standard treatments, which often rely on pharmaceuticals with potential side effects, light therapy focuses on harnessing natural processes to improve well-being, which could make it a safer and more appealing option for many patients.
What evidence suggests that systemic light exposure might be an effective treatment for preventing frailty in prostate cancer patients?
Research has shown that bright white light (BWL) therapy, which participants in this trial may receive, might lessen the negative effects of hormone treatment in older men with prostate cancer. These effects include fatigue and muscle weakness. Studies suggest that BWL can reduce tiredness and feelings of depression in these patients. Exposure to bright white light may increase energy levels and reduce exhaustion. Although still in early stages, the hope is that this light therapy could improve the overall quality of life for those weakened by their treatment.24678
Who Is on the Research Team?
William Dale
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
This trial is for older prostate cancer patients starting hormone therapy with minimal disease burden, who can sign consent and have a life expectancy of 6 months or more. It's not for those with severe sleep disorders, eye diseases affecting light processing, psychological impairments, night shift workers, recent secondary cancers, plans to travel across time zones during treatment, uncontrolled illnesses or infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo bright white light (BWL) or dim white light (DWL) treatment using Luminette glasses for 30 minutes every morning
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Systemic Light Exposure
Trial Overview
The study tests if systematic light exposure prevents frailty symptoms caused by hormone therapy in older men with prostate cancer. Frailty includes fatigue, slow walking speed, reduced activity levels, muscle loss and weakness. The trial involves questionnaires and actigraphy (movement monitoring) to assess the effects.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
Light Exposure to Prevent Frailty in Prostate Cancer Patients
This pilot trial studies how well systemic light exposure works in preventing frailty in older patients with prostate cancer on hormonal therapy.
Study Details | NCT03419585 | The "PC-LIGHT" Study
The proposed study will provide information about systematic light exposure for the prevention of fatigue in prostate cancer patients undergoing radiation ...
3.
onclive.com
onclive.com/view/bright-white-light-may-offset-negative-effects-of-adt-in-older-men-with-prostate-cancerBright White Light May Offset Negative Effects of ADT in ...
For older patients with prostate cancer, bright white light could potentially mitigate the negative effects of androgen deprivation therapy ...
A Phase 2 Study of Bright White Light During Treatment ...
This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer ...
Bright White Light Therapy in Reducing Cancer-Related ...
This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer ...
Life course sun exposure and risk of prostate cancer
Our data and meta-analyses provide limited support for the hypothesis that increased exposure to sunlight may reduce prostate cancer risk.
Effectiveness and Safety of Bright Light Therapy in ...
Bright light therapy is considered a well-tolerated and easy to administer form of treatment with relatively low costs. Our systematic review is focused on the ...
Exposure to Light at Night and Risk of Cancer
A link between LAN exposure and increased risk for lung cancers, leukemias, and hepatocarcinomas in mice models has already been established, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.